Healthcare Industry News: InterMune
News Release - August 28, 2006
Zogenix, Inc. Names Founding Management TeamSAN DIEGO & HAYWARD, Calif.--(HSMN NewsFeed)--Aug. 28, 2006--Zogenix, Inc. is a privately held specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain. In conjunction with today's separate announcement of the company's $60 million Series A financing, Zogenix named its founding management team. The founding members are:
- Cam L. Garner, Chairman of the Board of Directors;
- Roger L. Hawley, Chief Executive Officer;
- Stephen J. Farr, Ph.D., President and Chief Operating Officer;
- Jonathan Rigby, Vice President of Business Development;
- Bret E. Megargel, Vice President of Finance and Corporate Development; and
- John J. Turanin, Vice President of Operations.
Roger L. Hawley joins the founding team of Zogenix as Chief Executive Officer with over 19 years of distinguished commercial pharmaceutical experience, having most recently served as Executive Vice President, Commercial and Technical Operations for InterMune (NASDAQ:INTM ) since 2003. Prior to joining InterMune, Mr. Hawley held senior executive level commercial roles with Prometheus Laboratories Inc., Elan Pharmaceuticals, Inc. (NYSE:ELN ), and GlaxoSmithKline (NYSE:GSK ), where he ended his fourteen-year career as Vice President of Sales - CNS/ GI Division in 2001. During his career, Mr. Hawley has had the unique opportunity to participate in the launch and commercialization of three of the currently marketed triptan migraine therapies as well as other CNS products. Currently he serves on the board of Targeted Genetics (NASDAQ:TGEN ) and Alios Biopharma, Inc., a private biotechnology company.
Stephen J. Farr, Ph.D. brings over 20 years of drug delivery science and drug/device product development to his founding role of President and Chief Operating Officer. Dr. Farr most recently served as Senior Vice President and Chief Scientific Officer of Aradigm, Corp. (NASDAQ:ARDM ), where he served as scientific director for Aradigm's inhaled insulin program, and was technical director of the Intraject® program. While at Aradigm, Dr. Farr played a key leadership role in developing Intraject® sumatriptan to its current advanced stage of technical development.
Mr. Garner, Mr. Hawley, and Dr. Farr are joined by founding team members Jonathan Rigby, Bret E. Megargel, and John J. Turanin. Mr. Rigby joins Zogenix with over 16 years of pharmaceutical experience, most recently serving as Vice President of Business Development for Aradigm, Corp., where he led the original acquisition and subsequent strategic development of Intraject®. Mr. Rigby also serves as Vice Chair of the Association of Needle Free Injection Manufacturers.
Mr. Megargel has over 15 years of related healthcare experience, having most recently served as Vice President/General Manager for Planet Technologies, Inc., and Vice President, Business Development for Avera Pharmaceuticals, Inc.
Mr. Turanin adds over 20 years of pharmaceutical and medical device development experience, having most recently served as Vice President, Corporate Planning, and Program Management at Aradigm, Corp., where he led several product development programs, including Intraject® sumatriptan.
Zogenix, Inc., with offices in Hayward and San Diego, CA, is a private, specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain. The company's initial focus is the completion of the late-stage development and commercialization of Intraject® sumatriptan -- a needle-free, single-use, disposable, subcutaneous delivery system that will compete in the $2.5 billion triptan segment of the migraine market. Additional information on the company can be found at www.zogenix.com.
Intraject is a registered trademark of Zogenix, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.